A practical reference on c-Met signaling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-19. Anything still debated is marked as such rather than presented as settled.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Boehringer Ingelheim Austria has validated a method with cGMP (commercial good manufacturing practices) for production of pharmaceutical-grade DNA plasmids. They are able to process 200L of fermentation broth on an 800mL monolith. At BIA Separations, processing time of the tomato mosaic virus decreased considerably from the standard five days of manually intensive work to equivalent purity and better recovery in only two hours with a monolith column. Other viruses have been purified on monoliths as well. Affinity monoliths have also been applied to the isolation of nanoscale particles from human plasma. Tandem monolithic disks functionalized with chondroitin-6-sulfate and anti-apolipoprotein B-100 antibodies enabled the selective isolation of low-density lipoprotein in less than 30 minutes, while a monolith carrying an anti-CD61 antibody isolated platelet-derived extracellular vesicles in 19 minutes. Monolithic disks carrying antibodies against apoB-100, CD9, or CD61 were subsequently coupled online to asymmetric flow field-flow fractionation, allowing automated isolation and size fractionation of lipoproteins and extracellular-vesicle subpopulations. Extracellular-vesicle fractions obtained using these monolith-based systems have also been characterized by Raman spectroscopy and comprehensive two-dimensional gas chromatography, and used in quartz crystal microbalance studies of binding between extracellular-vesicle subpopulations and affinity ligands.
Produced by Patrick Uden, directed by Taghi Amirani, made by Uden Associates 6 August New York! New York!, about sewage; New York makes enough sewage each day to fill the Yankee Stadium ten times, with seven million people; it had 80,000 miles of electric cable; a new sewage tunnel 60 miles long, 800 ft below ground, was being built, to be finished in the next century - the New York City Water Tunnel No. 3 is expected to be finished by 2032 13 August Fatal Attraction, about road transport; Britain subsidised rail £2 per mile, West Germany was £5 per mile; Reinhard Gutter of Cologne; traffic calming hadmainly begun in West Germany, from 1976; John Whitelegg; transport psychologist Carina van Knippenburg of the University of Gronigen; in 1987, the Dutch government introduced rationing of car transport, also trialled in Hong Kong; Ian Catling, and road pricing; Martin Paget in Birmingham; Talib Rothengatter, and the resignation of the Dutch government in April 1989; Philip Goodwin; Martin Mogridge of UCL. Narrated by Simon Ward, produced by Stewart Lansley, directed by Andy Mayer, made by Juniper Productions 20 August The Defender, building a new fighter plane in Canada; Chris Ball, of Bristol Aerospace in Winnipeg, and Bob Diemert are building a fighter plane in Carman, Manitoba; Bob Diemert flew one of his restored Hurricane XII aircraft in the 1969 Battle of Britain; the Commemorative Air Force at Harlingen, Texas; his plane attempts to take off, but it is something akin to a scene from Those Magnificent Men in Their Flying Machines.
calculates the abundance of carbon-13 relative to carbon-12 in all methane molecules. For the random distribution (i.e. probability distribution), the probability of choosing a carbon-13 atom over a carbon-12 atom is
Sources: en.wikipedia.org
NH3 + 3 CH3CH2OH → N(CH2CH3)3 + 3 H2O The pKa of protonated triethylamine is 10.75, and it can be used to prepare buffer solutions at that pH. The hydrochloride salt, triethylamine hydrochloride (triethylammonium chloride [(CH3CH2)3NH]+Cl−), is a colorless, odorless, and hygroscopic powder, which decomposes when heated to 261 °C. Triethylamine is soluble in water to the extent of 112.4 g/L at 20 °C. It is also miscible in common organic solvents, such as acetone, ethanol, and diethyl ether. Laboratory samples of triethylamine can be purified by distilling from calcium hydride. In alkane solvents triethylamine is a Lewis base that forms adducts with a variety of Lewis acids, such as I2 and phenols. Owing to its steric bulk, it forms complexes with transition metals reluctantly.
The history of radiation protection begins at the turn of the 19th and 20th centuries with the realization that ionizing radiation from natural and artificial sources can have harmful effects on living organisms. As a result, the study of radiation damage also became a part of this history. While radioactive materials and X-rays were once handled carelessly, increasing awareness of the dangers of radiation in the 20th century led to the implementation of various preventive measures worldwide, resulting in the establishment of radiation protection regulations. Although radiologists were the first victims, they also played a crucial role in advancing radiological progress and their sacrifices will always be remembered. Radiation damage caused many people to suffer amputations or die of cancer. The use of radioactive substances in everyday life was once fashionable, but over time, the health effects became known. Investigations into the causes of these effects have led to increased awareness of protective measures. The dropping of atomic bombs during World War II brought about a drastic change in attitudes towards radiation. The effects of natural cosmic radiation, radioactive substances such as radon and radium found in the environment, and the potential health hazards of non-ionizing radiation are well-recognized. Protective measures have been developed and implemented worldwide, monitoring devices have been created, and radiation protection laws and regulations have been enacted. In the 21st century, regulations are becoming even stricter.
== Honours and awards == 2000 – Human Frontier Science Program Long-Term Postdoctoral Fellowship. 2004 – Career Development Award, Human Frontier Science Program 2007 – Starting Grant, European Research Council 2013 – Rector's Prize for Excellence in Research and Teaching, Hebrew University of Jerusalem 2015 – Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research 2018 – Michael Milken Prize for Excellence in Teaching.
The reaction pathway of this enzyme is key in regulating the synthesis and degradation of collagen, a vital protein necessary for multiple aspects of the body. Irregular levels of serum prolidase in the blood are indicative of various diseases and conditions in humans. Deficiency in prolidase leads to a rare, severe autosomal recessive disorder (prolidase deficiency) that causes many chronic, debilitating health conditions in humans. These phenotypical symptoms vary and may include skin ulcerations, mental retardation, splenomegaly, recurrent infections, photosensitivity, hyperkeratosis, and unusual facial appearance. Furthermore, prolidase activity was found to be abnormal compared to healthy levels in various medical conditions including but limited to: bipolar disorder, breast cancer, endometrial cancer, keloid scar formation, erectile dysfunction, liver disease, lung cancer, hypertension, melanoma, and chronic pancreatitis. In some cancers with increased levels of prolidase activity, such as melanoma, the differential expression of prolidase and its substrate specificity for dipeptides with proline at the carboxyl end suggests the potential of prolidase in becoming a viable, selective endogenous enzyme target for proline prodrugs. Serum prolidase enzyme activity is also currently being explored as a possible, reliable marker for diseases including chronic hepatitis B and liver fibrosis.
Sources: en.wikipedia.org
Duterte campaigned to eliminate illegal drugs in the country within three to six months, but later acknowledged he miscalculated the severity of the problem as he based his approach to that of Davao City during his tenure as the city's mayor. Stating it would take him his entire term to eradicate it, he cited the difficulty in border control due to the country's fragmented geography and lamented that several government officials and law enforcers were involved in drug trafficking. Before leaving office, he implored president-elect Bongbong Marcos to continue tackling the illegal drug problem, but declined an appointment offer as Marcos' drug czar, expressing a desire to retire. By the end of Duterte's term, the number of drug suspects killed since Duterte took office was officially tallied by the government as 6,252; human rights groups, however, claim drug casualties reached as high as 12,000 to 30,000. Various international publications and media companies had claimed that Duterte's anti-drugs campaign was a war against the poor due to the abject poverty of those arrested or killed. On June 19, 2018, 38 United Nations member states released a collective statement through the United Nations Human Rights Council, calling on the Philippines and Duterte to end the killings in the war on drugs and cooperate in investigating human rights abuses.
In the United States, a group of companies including OpenAI, Alphabet, and Meta signed a voluntary agreement with the Biden administration in July 2023 to watermark AI-generated content. In October 2023, Executive Order 14110 applied the Defense Production Act to require all US companies to report information to the federal government when training certain high-impact AI models. In the European Union (EU), the Artificial Intelligence Act includes requirements to disclose copyrighted material used to train generative AI systems, and to label any AI-generated output as such. In China, the Interim Measures for the Management of Generative AI Services introduced by the Cyberspace Administration of China regulates any public-facing generative AI. It includes requirements to watermark generated images or videos, regulations on training data and label quality, restrictions on personal data collection, and a guideline that generative AI services must "adhere to socialist core values". In 2021, UNESCO adopted the Recommendation on the Ethics of Artificial Intelligence, the first global standard-setting instrument on AI. It provides guidance to member states on issues including human rights, fairness, transparency, data governance, and environmental sustainability. The Group of Seven (G7) launched the Hiroshima AI Process in 2023, which produced international guiding principles and a voluntary code of conduct for developers of advanced AI systems.
=== Cell signalling === Citicoline may enhance cellular communication by increasing levels of neurotransmitters. The choline component of citicoline is used to create acetylcholine, which is a neurotransmitter in the human brain. Clinical trials have found that citicoline supplementation might improve focus and attention.
==== Illegal marketing settlement (2014) ==== In June 2010, health insurance network Blue Cross Blue Shield (BCBS) filed a lawsuit against Pfizer for allegedly illegally marketing drugs Bextra, Geodon and Lyrica. BCBS alleged that Pfizer used kickbacks and wrongly persuaded doctors to prescribe the drugs. According to the lawsuit, Pfizer handed out 'misleading' materials on off-label uses, sent over 5,000 doctors on trips to the Caribbean or around the United States, and paid them $2,000 honoraria in return for listening to lectures about Bextra. Despite Pfizer's claims that "the company's intent was pure" in fostering a legal exchange of information among doctors, an internal marketing plan revealed that Pfizer intended to train physicians "to serve as public relations spokespeople." The case was settled in 2014 for $325 million. Fearing that Pfizer is "too big to fail" and that prosecuting the company would result in disruptions to Medicare and Medicaid, federal prosecutors instead charged a subsidiary of a subsidiary of a subsidiary of Pfizer, which is "nothing more than a shell company whose only function is to plead guilty."
The gold in the county council's coat of arms symbolises the wealth of the area. Black is for both mining and the Black Mountains. The fountain is a medieval heraldic charge displayed as a roundel barry wavy argent and azure. It represents water and refers to both the water catchment area and the rivers and lakes. Thus, the arms contain references to the hills and mountains, rivers and lakes, water supply and industry. The crest continues the colouring of the arms. A tower has been used in preference to a mural crown, which alludes to the county's military history and remains. From the tower rises a red kite, a bird almost extinct elsewhere in Britain but thriving in Powys. The bird is a "semé of black lozenges" for the former coal mining industry, while the golden fleece it carries is a reference to the importance of sheep rearing in the county. The county motto is: Powys – the paradise of Wales (Welsh: Powys Paradwys Cymru).
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.